Elicio Therapeutics Inc expected to post a loss of 73 cents a share - Earnings Preview

Elicio Therapeutics

06/11/2024 13:56

* Elicio Therapeutics Inc  ELTX.OQ   ELTX.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 7 (estimated) for the period ending January 1 0001
    * 
    * ​LSEG's mean analyst estimate for Elicio Therapeutics Inc
is for
a loss of 73 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Elicio
Therapeutics Inc is 9.50​, above​ its last closing price
of $4.84. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.96       -0.96      -0.64     Beat    33.3
 Jan. 1 2024   -1.08       -1.09      -1.15     Missed  -5.5
 Jan. 1 0001   -1.03       -0.78      -1.75     Missed  -122.9
                                                        ​
 Sep. 30 2023  -0.80       -0.80      -1.27     Missed  -58.7
 ​​                                   -2.44             
                                      -1.50             ​
 Dec. 31 2022              -2.10      -2.10     Met     0
 Sep. 30 2022  -2.94       -3.60      -3.00     Beat    16.7
 This summary was machine generated November 6 at 13:56 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)